Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

About this update from Zealand Pharma A/s

[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Press release – No. 18 / 2025","length":29,"tagName":"p"},{"type":"text","content":"Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases ","length":154,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases","length":275,"tagName":"p"}]},{"val":[{"type":"text","content":"OTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30 million under certain pre-agreed conditions, and is eligible for potential preclinical, development, regulatory, and commercial milestone payments, for a potential total consideration of up to USD ~2.5 billion, with the majority representing commercial milestones, plus tiered royalties","length":391,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":666,"olType":false},{"type":"text","content":"Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, and OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies for unmet medical needs, today announce a multi-program strategic collaboration and license agreement to discover and develop novel therapeutics for metabolic diseases.","length":462,"tagName":"p"},{"type":"text","content":"The collaboration brings together Zealand Pharma’s deep expertise in obesity and metabolic health with OTR Therapeutics’ proprietary R&D platform,...

More updates from Zealand Pharma A/s